IL100402A0 - Use of il-4 to enhance immune response to immunogens in vaccines - Google Patents

Use of il-4 to enhance immune response to immunogens in vaccines

Info

Publication number
IL100402A0
IL100402A0 IL100402A IL10040291A IL100402A0 IL 100402 A0 IL100402 A0 IL 100402A0 IL 100402 A IL100402 A IL 100402A IL 10040291 A IL10040291 A IL 10040291A IL 100402 A0 IL100402 A0 IL 100402A0
Authority
IL
Israel
Prior art keywords
immune response
immunogens
vaccines
vaccine
enhance immune
Prior art date
Application number
IL100402A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL100402A0 publication Critical patent/IL100402A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
IL100402A 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines IL100402A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62980090A 1990-12-19 1990-12-19

Publications (1)

Publication Number Publication Date
IL100402A0 true IL100402A0 (en) 1992-09-06

Family

ID=24524543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL100402A IL100402A0 (en) 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines

Country Status (20)

Country Link
EP (1) EP0563254B1 (de)
JP (1) JPH06503830A (de)
CN (1) CN1063227A (de)
AT (1) ATE129900T1 (de)
AU (1) AU9161591A (de)
CA (1) CA2098726A1 (de)
CZ (1) CZ119993A3 (de)
DE (1) DE69114519T2 (de)
DK (1) DK0563254T3 (de)
ES (1) ES2079851T3 (de)
FI (1) FI932759A (de)
GR (1) GR3018820T3 (de)
HU (1) HUT68529A (de)
IE (1) IE70453B1 (de)
IL (1) IL100402A0 (de)
OA (1) OA09863A (de)
PT (1) PT99838A (de)
SK (1) SK59393A3 (de)
WO (1) WO1992011030A1 (de)
ZA (1) ZA919907B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
HUT76101A (en) * 1994-04-08 1997-06-30 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
EP0275300B1 (de) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Rekombinanter impfstoff
JP3485184B2 (ja) * 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
ATE133074T1 (de) * 1990-03-21 1996-02-15 Schering Corp Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen

Also Published As

Publication number Publication date
SK59393A3 (en) 1994-03-09
ATE129900T1 (de) 1995-11-15
EP0563254B1 (de) 1995-11-08
FI932759A0 (fi) 1993-06-16
OA09863A (en) 1994-08-15
FI932759A (fi) 1993-06-16
CN1063227A (zh) 1992-08-05
CA2098726A1 (en) 1992-06-20
DE69114519D1 (de) 1995-12-14
ES2079851T3 (es) 1996-01-16
ZA919907B (en) 1992-08-26
JPH06503830A (ja) 1994-04-28
AU9161591A (en) 1992-07-22
DE69114519T2 (de) 1996-04-04
EP0563254A1 (de) 1993-10-06
CZ119993A3 (en) 1994-02-16
DK0563254T3 (da) 1996-02-12
IE70453B1 (en) 1996-11-27
IE914436A1 (en) 1992-07-01
GR3018820T3 (en) 1996-04-30
PT99838A (pt) 1992-12-31
HU9301797D0 (en) 1993-10-28
WO1992011030A1 (en) 1992-07-09
HUT68529A (en) 1995-06-28

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
NZ218825A (en) Use of low dosages of interferon as adjuvants for vaccines
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
IL96893A0 (en) Vaccines against cancer and infectious diseases
IL103121A0 (en) Recombinant dna-derived bordetella toxin subunit analogs
ES2149776T3 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
CO4910171A1 (es) Vacunas comprendiendo bajas dosis de antigenos de difteria, tetano y tos ferina acelular ( dtpa )
ZA919907B (en) Use of il-4 to enhance immune response to immunogens in vaccines
ZA912037B (en) Use of il-4 to enhance immune response to infectious antigenic challenges
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
EP0414816A4 (en) Induction of tolerance to a foreign antigen
CA2331086A1 (en) Hepatitis vaccine
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
NZ501427A (en) Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств
OA08974A (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
Rethy Jr et al. The purification-method-dependent immunogenicity of diphtheria toxoid. II. The human immunogenicity of differently purified toxoids.
Báthori et al. Immuno-modulation with inactivated bacterium-suspensions or derivatives. VI. The immuno-adjuvanting activity of liposomes combined with lipid-A and B. pertussis vaccine.